Leukemia
Changing Paradigms in the Treatment of Acute Myeloid Leukemia in Older Patients
Abstract: Approximately 70% of breast tumors are ER+ and HER2–. First-line treatment that combines endocrine therapy (AIs, SERMs, and SERDs) with a CDK4/6 inhibitor is the […]
Abstract: Approximately 70% of breast tumors are ER+ and HER2–. First-line treatment that combines endocrine therapy (AIs, SERMs, and SERDs) with a CDK4/6 inhibitor is the […]
Abstract: Colorectal cancer is the third most prevalent cancer type in the United States, with an alarming incidence and mortality rate, especially among individuals younger than […]
Abstract: The staging of intrahepatic cholangiocarcinoma (ICC) is complex, and there is no consensus among international cancer groups on how to most appropriately select candidates with […]
A Review of Selected Presentations from SABCS 2022 • San Antonio, TX • December 6-10, 2022 EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care […]
A Review of Selected Presentations From the 2022 San Antonio Breast Cancer Symposium® • December 6-11, 2022 • San Antonio, Texas Sacituzumab Govitecan vs Treatment of […]
A Review of Selected Presentations from ASCO 2022, Chicago, IL, June 3-7, 2022; ESMO Breast Cancer Congress 2022, Berlin, Germany, May 3-5 2022; and ESMO Congress […]
Abstract: Kidney cancer is the eighth most commonly diagnosed cancer in the United States, and nearly one-third of patients have locally advanced or metastatic disease […]
Overview • Brain metastasis in patients with metastatic renal cell carcinoma generally signifies a poor prognosis. • Surgical resection is an option for patients with […]
Abstract: The non–clear cell renal cell carcinomas (nccRCCs) are a diverse group of rare-variant renal carcinomas. Each subtype harbors a distinct cell of origin and […]